How to access Xenpozyme from Oman, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24
An Omani patient with confirmed acid sphingomyelinase deficiency (ASMD), historically referred to as Niemann-Pick disease type B, and in some presentations as type A/B, may receive a prescription for Xenpozyme (olipudase alfa) from their treating metabolic specialist, paediatric geneticist, or pulmonologist. Xenpozyme is FDA-approved in the United States as an enzyme-replacement therapy for non-central-nervous-system manifestations of ASMD in paediatric and adult patients. Because ASMD is ultra-rare and Xenpozyme is not yet routinely stocked in Oman hospital pharmacies, your specialist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Xenpozyme in Oman
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Xenpozyme is an intravenous recombinant human acid sphingomyelinase. It is administered via a dose-titration protocol, starting at a low dose and escalating every two weeks to the target maintenance dose, to reduce the risk of infusion-associated reactions that can accompany the clearance of sphingomyelin stores early in treatment. Once maintenance is reached, infusions are given every two weeks. The manufacturer is Sanofi. Eligibility requires biochemical and/or genetic confirmation of ASMD (SMPD1 variant and/or deficient acid sphingomyelinase activity). Your specialist will confirm the diagnosis, assess organ-system burden (lung diffusion capacity, spleen and liver volume, platelet count, lipid profile), and coordinate the titration and monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Xenpozyme legally importable into Oman?
Yes, through the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) named-patient import framework. Oman has a mature named-patient mechanism that has supported cross-border access to rare-disease enzyme-replacement therapies for many years.
The DGPADC named-patient route allows an Oman-licensed physician to request import of a medicine that is not locally registered when: (a) the medicine has been approved by a recognised reference authority (FDA qualifies), (b) there is no clinically equivalent locally registered alternative, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are reviewed by the DGPADC Drug Sector. For ultra-rare conditions like ASMD, where no local alternative exists and the clinical rationale is diagnosis-driven, the submission is straightforward to frame.
How the pathway works, step by step
- Consultation with your treating specialist. The decision to prescribe Xenpozyme is a clinical one, based on ASMD confirmation and organ-system burden. Your specialist documents the rationale and the titration plan.
- Infusion-facility identification. A Oman tertiary metabolic or paediatric centre equipped for bi-weekly infusions with infusion-reaction management capability accepts the case.
- DGPADC named-patient application. Your physician or the hospital's importing pharmacy files an application including clinical rationale, diagnostic confirmation, patient identifier, product details, titration schedule, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Xenpozyme requires refrigerated handling and ships with validated cold-chain packaging and continuous temperature logging end to end.
- Arrival and titration start. The infusion centre receives the product and begins the dose-titration protocol under your specialist's care. Reserve Meds coordinates the next cycle ahead of depletion.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming ASMD diagnosis (SMPD1 variant and/or enzyme assay), organ-system status, and Xenpozyme as the indicated therapy
- Verification of their Oman medical licence (SCFHS / MOH)
- A current prescription naming the product, the titration schedule, and the target maintenance dose
- Patient identifier (anonymised reference preferred)
- The identified infusion facility and its cold-chain and infusion-reaction handling capability
Reserve Meds provides a physician documentation kit bundling the templates DGPADC reviewers expect to see for named-patient import of cold-chain enzyme-replacement therapies with titration protocols.
Costs and timing
The cost of Xenpozyme is weight-dependent and scales with the titration protocol. Medicine price: quote on request. You get a written quote for your case before you commit. Cold-chain logistics, DGPADC documentation handling, and coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake, with the medicine cost shown separately from service charges so your family can see the breakdown.
We give you a written timeline estimate for your case before you commit. Subsequent cycles are scheduled to match the bi-weekly titration and maintenance calendar.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A brief culturally-aware note: ASMD has a higher reported prevalence in certain regional communities, and Oman tertiary metabolic centres have experience managing lysosomal storage disorders. Ramadan and Hajj seasons can affect infusion scheduling; our team coordinates cycle timing with your family's preferences and your hospital's calendar.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Xenpozyme specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for DGPADC review, including diagnostic-attestation templates for ASMD.
- Logistics. Cold-chain shipment and chain-of-custody coordination with temperature logging.
- Dedicated case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating specialist and the infusion facility.
Frequently asked
Is this legal in Oman? Yes, when executed through the DGPADC named-patient framework with appropriate documentation and a licensed administering facility. See our trust and compliance page for our methodology.
Does Xenpozyme treat the neurological form of Niemann-Pick? Xenpozyme addresses non-CNS manifestations of ASMD. It is not approved for the neuronopathic (type A) form. Your specialist will confirm the subtype and what the therapy is expected to address.
Why the dose-titration protocol? Gradual dose escalation is built into Xenpozyme's labeling to reduce the risk of infusion-associated reactions that can occur as sphingomyelin is cleared. Your infusion team follows the manufacturer's titration schedule.
What about paediatric patients? Xenpozyme is approved for both paediatric and adult patients. Paediatric dosing follows the same titration framework adjusted for weight. Your paediatric metabolic specialist will lead the plan.
Will private insurance cover this? Cash-pay is the default. Some Oman private insurers reimburse named-patient imports for ultra-rare enzyme-replacement therapies on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Xenpozyme coordination in Oman, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-24.
Frequently asked questions
How can I get Xenpozyme in Oman if it is not approved or available there?
Reserve Meds coordinates US-sourced Xenpozyme for patients in Oman through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Oman and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Xenpozyme in Oman through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Xenpozyme. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Oman, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Xenpozyme in Oman through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Xenpozyme to a patient in Oman?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Xenpozyme to your treating physician or hospital pharmacy in Oman, with appropriate handling for the product.
How long does it take, and what does Xenpozyme in Oman cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Xenpozyme in Oman?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.